Drug intelligence / Profile preview

SYP-2583

Development stage: Preclinical
Lead developer: Samyang Holdings Biopharm Group
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

SYP-2583 is an investigational mRNA vaccine candidate being developed by Samyang Holdings Biopharm Group for the prevention or treatment of Hepatitis C Virus (HCV) infection. The vaccine is formulated using Samyang's proprietary SENS™ (Samyang Elucidated Nanoparticle System) platform, which utilizes nanoparticle technology to facilitate the stable delivery and cellular uptake of mRNA. Currently in the preclinical stage, SYP-2583 is designed to induce a robust immune response against HCV by enabling the expression of viral antigens within the host, addressing a significant global need for effective HCV prevention and therapeutic strategies.

Beyond the preview

Go deeper on SYP-2583.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SYP-2583.

Explore the full profile